Citations

Clear

4093 citation(s) found for "Yu, Jonathan".

Health-Related Quality of Life (HRQoL) in Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Treated with Polatuzumab Vedotin, Rituximab, Cyclophosphamide, Doxorubicin and Prednisone (Pola-R-CHP) Versus Rituximab, Cyclophosphamide, Doxorubicin, Vincristin
Friedberg, Jonathan W. , Thompson, Carrie A. , Zhang, Huilai , Thiéblemont, Catherine , Hu, Bei , Fonseca, Gustavo , Kim, Won-Seog, Campinha‐Bacote, Avrita, Yan, Mark, Hirata, Jamie , Sugidono, Matthew , Lee, Calvin , Sharman, Jeff P. , Trněný, Marek , Morschhauser, Franck , Salles, Gilles , Reagan, Patrick Michael , Hertzberg, Mark , Smolewski, Piotr , Martelli, Maurizio , Mehta, Amitkumar

Mayo Clinic

Blood | November 28, 2022 | Volume: 140 | Issue: Supplement 1 | Pages: 6623-6626

10.1182/blood-2022-157761 Get It

The relevance of rich club regions for functional outcome post‐stroke is enhanced in women
Bonkhoff, Anna K. , Schirmer, Markus D. , Hong, Sung‐Min , Regenhardt, Robert W. , Donahue, Kathleen, Nardin, Marco, Etherton, Mark R. , Hancock, Brandon L., Mocking, Steven J. T. , McIntosh, Elissa C. , Donatti, Amanda , Heitsch, Laura , Jiménez-Conde, Jordi , Kittner, Steven J. , Levi, Christopher , Rosand, Jonathan, Schmidt, Reinhold , Sharma, Pankaj , Słowik, Agnieszka , Sousa, Alessandro , Stanne, Tara M. , Strbian, Daniel , Thijs, Vincent , Wassélius, Johan , Woo, Daniel , Zand, Ramin, McArdle, Patrick F. , Worrall, Bradford B. , Maguire, Jane , Wu, Ona , Rost, Natalia S. , Zand, Ramin , Strbian, Daniel , Regenhardt, Robert W , Wu, Ona , Zand, Ramin , Bretzner, Martin , Hong, Sungmin, Dalca, Adrian Vasile , Giese, Anne‐Katrin , Attia, John , Cole, John W. , Griessenauer, Christoph J. , Holmegaard, Lukas , Jood, Katarina , Lemmens, Robin , McDonough, Caitrin W. , Meschia, James F. , Phuah, Chia‐Ling , Ropele, Stefan , Rosand, Jonathan M. , Roquer, Jaume , Rundek, Tatjana , Sacco, Ralph L. , Tatlisumak, Turgut , Vagal, Achala , Jern, Christina , Lindgren, Arne G.

Mayo Clinic

Human Brain Mapping | November 28, 2022 | Volume: 44 | Issue: 4 | Pages: 1579-1592

10.1002/hbm.26159 | PMID 36440953 Get It

Abstract This study aimed to investigate the influence of stroke lesions in predefined highly interconnected (rich‐club) brain regions on functional outcome post‐stroke, determine their spatial specificity and explore the effects of biological sex on their relevance. We analyzed MRI data recorded at index stroke and ~3‐months modified Rankin Scale (mRS) data from patients with acute ischemic stroke enrolled in the multisite MRI‐GENIE study. Spatially normalized structural stroke lesions were parcellated into 108 atlas‐defined bilateral (sub)cortical brain regions. Unfavorable outcome (mRS > 2) was modeled in a Bayesian logistic regression framework. Effects of individual brain regions were captured as two compound effects for (i) six bilateral rich club and (ii) all further non‐rich club regions. In spatial specificity analyses, we randomized the split into “rich club” and “non‐rich club” regions and compared the effect of the actual rich club regions to the distribution of effects from 1000 combinations of six random regions. In sex‐specific analyses, we introduced an additional hierarchical level in our model structure to compare male and female‐specific rich club effects. A total of 822 patients (age: 64.7[15.0], 39% women) were analyzed. Rich club regions had substantial relevance in explaining unfavorable functional outcome (mean of posterior distribution: 0.08, area under the curve: 0.8). In particular, the rich club‐combination had a higher relevance than 98.4% of random constellations. Rich club regions were substantially more important in explaining long‐term outcome in women than in men. All in all, lesions in rich club regions were associated with increased odds of unfavorable outcome. These effects were spatially specific and more pronounced in women.
The role of neurofilament light in genetic frontotemporal lobar degeneration
Zetterberg, Henrik , Teunissen, Charlotte E. , Kühle, Jens , Boxer, Adam L. , Rohrer, Jonathan D. , Mitic, Laura L. , Nicholson, Alexandra M., Pearlman, Rodney , McCaughey, Stella, Tatton, Nadine , Teunissen, Charlotte E , Kuhle, Jens , Boxer, Adam , Rohrer, Jonathan D , Mitic, Laura , Pearlman, Rodney , Tatton, Nadine , Zetterberg, Henrik , Swieten, John C. van

Mayo Clinic

Brain Communications | November 26, 2022 | Volume: 5 | Issue: 1 | Pages: No page available

10.1093/braincomms/fcac310 | PMID 36694576 Get It

Abstract Genetic frontotemporal lobar degeneration caused by autosomal dominant gene mutations provides an opportunity for targeted drug development in a highly complex and clinically heterogeneous dementia. These neurodegenerative disorders can affect adults in their middle years, progress quickly relative to other dementias, are uniformly fatal and have no approved disease-modifying treatments. Frontotemporal dementia, caused by mutations in the GRN gene which encodes the protein progranulin, is an active area of interventional drug trials that are testing multiple strategies to restore progranulin protein deficiency. These and other trials are also examining neurofilament light as a potential biomarker of disease activity and disease progression and as a therapeutic endpoint based on the assumption that cerebrospinal fluid and blood neurofilament light levels are a surrogate for neuroaxonal damage. Reports from genetic frontotemporal dementia longitudinal studies indicate that elevated concentrations of blood neurofilament light reflect disease severity and are associated with faster brain atrophy. To better inform patient stratification and treatment response in current and upcoming clinical trials, a more nuanced interpretation of neurofilament light as a biomarker of neurodegeneration is now required, one that takes into account its relationship to other pathophysiological and topographic biomarkers of disease progression from early presymptomatic to later clinically symptomatic stages.
Multicenter Registry Using Propensity Score Analysis to Compare a Novel Transport/Preservation System to Traditional Means on Postoperative Hospital Outcomes and Costs for Heart Transplant Patients
Leacche, Marzia , Copeland, Hannah , Shudo, Yasuhiro , Molina, Ezequiel J., Stukov, Yuriy , Philpott, Jonathan M. , Kawabori, Masashi , Schroder, Jacob N. , D’Alessandro, David, Molina, Ezequiel , Pham, Si M. , Voigt, Jeffrey , Wolfe, Stanley B. , Jacobs, Jeffrey P. , Meyer, Dan M , Silvestry, Scott

Mayo Clinic

ASAIO Journal | November 18, 2022 | Volume: 69 | Issue: 4 | Pages: 345-349

10.1097/mat.0000000000001844 | PMID 36399786 Get It

The standard method for cardiac allograft preservation for the past 50 years has been static storage using crushed ice. A heart transplant transportation system designed to improve preservation quality with temperature monitoring, the Paragonix SherpaPak Cardiac Transport System (SCTS), was evaluated for its impact on postoperative costs relative to conventional ice storage. Observational US multicenter registry data collected during the August 2015 to November 2021 timeframe from 12 transplant hospitals were analyzed using logistic regression analysis and propensity matching to balance measured baseline covariates and to reduce selection bias. Hospital cost and outcome data post-transplant were then evaluated using various statistical methods. One hundred seventy-four (174) patients were identified resulting in 87 matches. Baseline characteristics were similar between groups. The SCTS group had a significantly lower proportion of ICU days on post-transplant mechanical circulatory support ( p < 0.0001); significantly fewer patients on extracorporeal membrane oxygenation ( p = 0.017); and significantly fewer patients experiencing severe primary graft dysfunction (PGD) ( p = 0.03). Overall hospital plus mechanical circulatory support post-transplant costs were significantly lower by $26.7K in the CTS cohort ( p = 0.03). Use of the SCTS is associated with improved clinical outcomes resulting in significantly lower overall hospital care costs.
Antibodies as drugs—a Keystone Symposia report
Cable, Jennifer, Wiltshire, Timothy D. , Mousa, Jarrod J. , Humphreys, David P., Breij, Esther C.W. , Bruhns, Pierre , Broketa, Matteo , Furuya, Genta , Hauser, Blake M. , Mahévas, Matthieu , Kwong, Peter D. , Davis, Jonathan H. , Brewis, Neil , Keyt, Bruce A. , Fennemann, Felix L. , Dussupt, Vincent , Rawi, Reda , Wolters, Rachael M. , Geuijen, Cecile, Sleeman, Matthew A. , Pengo, Niccolò , Donnellan, Francesca R. , Saphire, Erica Ollmann , Hayday, Adrian , Carfı́, Andrea , Cantaert, Tineke , Tripathi, Prabhanshu , Sivasubramanian, Arvind, Kim, Philip M. , Richardson, Eve , Leventhal, Daniel

Mayo Clinic

Annals of the New York Academy of Sciences | November 16, 2022 | Volume: 1519 | Issue: 1 | Pages: 153-166

10.1111/nyas.14915 | PMID 36382536 Get It

AbstractTherapeutic antibodies have broad indications across diverse disease states, such as oncology, autoimmune diseases, and infectious diseases. New research continues to identify antibodies with therapeutic potential as well as methods to improve upon endogenous antibodies and to design antibodies de novo. On April 27–30, 2022, experts in antibody research across academia and industry met for the Keystone symposium “Antibodies as Drugs” to present the state‐of‐the‐art in antibody therapeutics, repertoires and deep learning, bispecific antibodies, and engineering.
SURG-13. SYSTEMATIC REVIEW AND META-ANALYSIS OF IMPACT OF EXTENT OF RESECTION ON SURVIVAL ON GLIOBLASTOMA, IDH-WILDTYPE, WHO GRADE 4 (WHO 2021)
Germanwala, Anand V. , Lee, Jonathan , Jusué-Torres, Ignacio , Lee, Jonathan Wei Jie , Burns, Terry C. , Parney, Ian F.

Mayo Clinic

Neuro-Oncology | November 14, 2022 | Volume: 24 | Issue: Supplement_7 | Pages: vii254-vii254

10.1093/neuonc/noac209.979 Get It

Abstract BACKGROUND Glioblastoma diagnostic criteria have been redefined with the 5th edition of WHO classification of tumors of the central nervous system. Glioblastomas are defined as IDH wildtype diffuse astrocytic glioma tumors with one of the following features: microvascular proliferation, or necrosis, or TERT promoter mutation, or EGFR gene amplification, or +7/-10 chromosome copy number changes. The aim of this study is to establish the impact of extent of resection in overall survival (OS) and progression free survival (PFS) in glioblastoma, IDH-wildtype (WT), WHO grade 4 (WHO 2021). METHODS Systematic literature search was performed using the following databases: PubMed, Web of Science, Cochrane Central Register of Controlled Trials, Cochrane Database of Systematic Reviews and ClinicalTrials.gov to identify studies comparing OS and PFS after gross total resection (GTR) vs subtotal resection (STR) or biopsy for glioblastoma IDH-WT. Prognostic hazard ratios (HR) for OS and PFS were analyzed using a random-effects model. RESULTS We identified 1439 publications. Nine studies met inclusion/exclusion criteria. 788 patients underwent GTR out of 1818. The meta-analysis showed a significant increase in OS and PFS duration when undergoing GTR for glioblastoma IDH-WT with a median OS of 20 months 95% CI (17-25) compared to 12 months 95% CI (9-15) for STR or biopsy and a median PFS of 11 months 95% CI (9-12) for GTR compared to 7 months 95% CI (5-7) for STR or biopsy respectively. GTR showed a 49% significant reduction of mortality risk HR=0.51 95%CI (0.42-0.59) and a 44% significant reduction of progression risk HR=0.56 95%CI (0.41-0.71) compared to STR or biopsy. CONCLUSIONS This systematic review indicates that GTR may be associated with improved OS and PFS compared to STR or biopsy for Glioblastoma, IDH-WT, WHO grade 4 (WHO 2021). However, this is limited by variable study design and significant clinical and methodological heterogeneity among studies.
Rescue Endovascular Treatment of Patients With Emergent Large Vessel Occlusion Attributed to Intracranial Atherosclerosis: A Systematic Review and Meta‐Analysis
Chalhoub, Reda , Lena, Jonathan , Zaidat, Osama O. , Spiotta, Alejandro M , Kasab, Sami Al , Almallouhi, Eyad , Murad, Mohammad Hassan, Almallouhi, Eyad , Murad, M. Hassan , Kicielinski, Kimberly , Brennan, Emily , Havenon, Adam de

Mayo Clinic

Stroke: Vascular and Interventional Neurology | November 11, 2022 | Volume: 3 | Issue: 1 | Pages: No page available

10.1161/svin.122.000510 | PMID 41585755 Get It

Background Patients with acute stroke presenting with large vessel occlusion secondary to intracranial atherosclerosis (ICAS‐LVO) may require rescue therapy (RT) in addition to mechanical thrombectomy to achieve and maintain successful recanalization. We performed a systematic review and meta‐analysis of comparative studies that reported outcomes of RT in patients with ICAS‐LVO to evaluate its safety and efficacy. Methods Databases searched include PubMed, CINAHL Complete, and Scopus from database date of inception through August 17, 2021. We included comparative studies that reported the outcomes of ICAS‐LVO RT compared with outcomes of patients with ICAS‐LVO who did not undergo RT or to those patients presenting with embolic large vessel occlusion (non–ICAS‐LVO). Meta‐analysis using the random‐effects model was used to combine estimates reporting odds ratios (ORs) and 95% CIs. Results A total of 9 nonrandomized studies were included: 5 studies in ICAS‐LVO RT versus ICAS‐LVO non‐RT analysis and 5 in ICAS‐LVO RT versus non‐ICAS LVO analysis. Rescue treatments included intra‐arterial antiplatelets, angioplasty, stenting, or a combination of treatments. Compared with non‐RT ICAS‐LVO, RT was associated with an increased favorable 90‐day outcome (OR, 3.19 [95% CI, 1.91–5.32]; I 2 = 14%) and decreased 90‐day mortality (OR, 0.35 [95% CI, 0.16–0.76]; I 2 = 21%). In the analysis of ICAS‐LVO RT versus embolic LV, the incidence of favorable 90‐day outcome and 90‐day mortality did not differ between ICAS‐LVO RT and non–ICAS‐LVO (OR, 0.97 [95% CI, 0.58–1.64; I 2 = 50%]; and OR, 1.22 [95% CI, 0.90–1.66; I 2 = 0%], respectively). Conclusions Rescue treatment is likely associated with better outcomes in patients with ICAS‐LVO. The outcomes of patients with ICAS‐LVO who receive RT may be comparable with patients with embolic large vessel occlusion (non–ICAS‐LVO).
Developing a research agenda on climate change and health in primary care
Temte, Jonathan L. , Barrett, Bruce , Erickson, Rodney A. , Bell, Cristalyne , Erickson, Rodney

Mayo Clinic

Family Practice | November 10, 2022 | Volume: 40 | Issue: 3 | Pages: 519-521

10.1093/fampra/cmac130 | PMID 36461915 Get It

Dizziness as a missed symptom of central nervous system pathology: A review of malpractice cases
Ghaith, Summer , Voleti, Sandeep S. , Bellolio, Fernanda , Edlow, Jonathan A. , Lindor, Rachel A. , Bellolio, M Fernanda , Lindor, Rachel A

Mayo Clinic

Academic Emergency Medicine | November 10, 2022 | Volume: 30 | Issue: 5 | Pages: 589-591

10.1111/acem.14627 | PMID 36354754 Get It